Incruse Ellipta

Incruse Ellipta

umeclidinium bromide

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Umeclidinium Br
Indications/Uses
Maintenance bronchodilator treatment to relieve symptoms associated w/ COPD.
Dosage/Direction for Use
Contraindications
Hypersensitivity. Severe milk-protein allergy.
Special Precautions
Asthma. Should not be used for the relief of acute symptoms ie, rescue therapy for the treatment of acute episodes of bronchospasm. Discontinue use if paradoxical bronchospasm occur. Severe CV disorders, narrow-angle glaucoma or urinary retention. Not studied in severe hepatic impairment. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Nasopharyngitis, upper resp tract infection, UTI, sinusitis; tachycardia; cough; dysguesia.
Drug Interactions
Increase antimuscarinic adverse effects w/ other antimuscarinic-containing drugs.
ATC Classification
R03BB07 - umeclidinium bromide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, anticholinergics.
Presentation/Packing
Form
Incruse Ellipta inhalation powd 62.5 mcg/dose
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in